Free morning briefing · 07:30 weekdays
The RNS that moves prices, in your inbox before the open.
AI-ranked movers and high-impact RNS across the FTSE 100, 250, SmallCap and AIM — one short email, every market day.
Get the briefing
HIK

Hikma Pharmaceuticals PLC

HIKLSEUnited KingdomHealthcareDrug Manufacturers - Specialty & GenericFTSE 250

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products…more

P/E12.12xP/B1.83xROIC12.4%Dividend yield4.0%
£3.31B
Market Cap
EV: £5.15B
MOM4
QUAL6
VAL8
RSK5
HIK
£3.31B
Market Cap · EV £5.15B

Hikma Pharmaceuticals PLC

MOM4
QUAL6
VAL8
RSK5

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products…more

Latest RNS from Hikma Pharmaceuticals PLC

All HIK news → · RNS daily feed

Analyst consensus: Buy

As of 21 Sept 2026, 12 analysts rate Hikma Pharmaceuticals PLC a Buy, with 92% buy ratings and a mean price target of 2,024p (range 1,721p–2,642p), +27% vs the current price.

Strong buy: 3Buy: 8Hold: 1Sell: 0Strong sell: 0

Full analyst history →

Valuation vs peers

Peer-relative fair value estimate: 3,261p against a current price of 1,603p (+103%), based on EV/EBITDA.

More Healthcare companies